Surgical site infections (SSIs) are a large and unsolved health problem worldwide. SSIs are a common postoperative complication in vascular, obstetric, gynecologic, gastric, thoracic, and cardiovascular surgery. It extends hospitalisation and contributes to a significant morbidity and mortality.
Similarly, post surgery adhesions are associated with serious complications, including higher risk of morbidity and mortality.
With increased hospitalisation timings, longer operative times, and longer length of hospital stay, post-surgical adhesions pose a great health and financial burden.
We have developed a product candidate, BR201, as a solution helping to prevent SSIs and adhesions formation.
BR201 acts as a strong protective barrier and it has already demonstrated efficacy in clinical tests.
- A biomolecule with an elegant mode of action that effectively targets and dissolves infection and bacteria
- No side effects as the molecule breaks infection into basic amino acids
- Life saving
- Very high interest amongst surgeons in this field